Seelos Therapeutics Announces Proposed Public Offering of Common Stock
Seelos Therapeutics (Nasdaq: SEEL) has initiated a proposed underwritten public offering of common stock, with the offering subject to market conditions. The company will sell all shares and may grant underwriters an option for an additional 15% for over-allotments. Proceeds will partially repay outstanding convertible promissory notes and support product candidate development. The offering will be conducted under an effective shelf registration statement filed with the SEC. BTIG is the sole book-running manager for this offering.
- Proceeds intended for partial repayment of convertible promissory notes.
- Funds will also support the advancement of product candidates.
- Potential dilution of existing shares due to the offering.
NEW YORK, Jan. 25, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has commenced a proposed underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters an option to purchase up to an additional
BTIG is acting as the sole book-running manager for the offering.
Seelos intends to use a portion of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes and the remainder for general corporate purposes and to advance the development of its product candidates.
The securities described above will be offered by Seelos pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-251356) previously filed with the Securities and Exchange Commission (the "SEC") on December 15, 2020, amended on December 22, 2020, and declared effective by the SEC on December 23, 2020. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by visiting the SEC's website at www.sec.gov or by contacting BTIG, LLC, Attention: Equity Capital Markets, 65 East 55th Street, New York, NY 10022, by calling (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
Forward-Looking Statements:
This press release contains forward-looking statements related to Seelos Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the proposed underwritten public offering and the anticipated use of proceeds from the offering and other matters that are described in Seelos' most recent periodic reports filed with the SEC, including Seelos' Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 17, 2020, subsequent Quarterly Reports on Form 10-Q and the preliminary prospectus supplement and the accompanying prospectus related to the proposed public offering filed with the SEC on or about the date hereof, including risks and uncertainties associated with general economic and market conditions and the satisfaction of customary closing conditions and the other risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and Seelos disclaims any intent or obligation to update these forward-looking statements except as required by law.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-announces-proposed-public-offering-of-common-stock-301214412.html
SOURCE Seelos Therapeutics, Inc.
FAQ
What is the proposed public offering by Seelos Therapeutics?
When was the offering announced?
What will Seelos do with the proceeds from the offering?
Who is managing Seelos Therapeutics' stock offering?
What are the terms of the public offering for SEEL?
